… /paraganglioma is essential to ascertain clinical behavior … ), and provide personalized
management and follow-up. … that informed personalized genetic-driven treatment should be …

… impacts on further more personalized management strategy. … that a pheochromocytoma or
paraganglioma can be … with neck and skull base paragangliomas. The very high diagnostic …

… It is likely that advances in such molecular targeted therapies will play an essential role in
the future treatment of these tumors, with more personalized therapy options paving the way …

Pheochromocytomas and paragangliomas (PCC/PGLs) are … decisive factors for best clinical
management of PCC/PGL include … clinicians summarizing current management of PCC/PGL …

… PPGL management The Endocrine Society clinical practice guidelines for phaeochromocytoma
and paraganglioma that were published in 2014 recommend personalized management …

The terms paraganglioma (PGL) and pheochromocytoma (Pheo) were first mentioned in
1908 and 1912 respectively when pathologists Henri Alezais, Felix Peyron, and Ludwig Pick …

… during the course of treatment as 30-40% of pheochromocytomas are associated with …
procedure to cure patients with pheochromocytoma. The transabdominal and retroperitoneal …

… The surgical approach is a high-risk procedure requiring perioperative management by a …
management in patients with pheochromocytomas and sympathetic paragangliomas. …

… The choice of the appropriate treatment should be based on multidisciplinary and
personalized approach taking into account the rarity and the variability of these tumors. …

… Pheochromocytomas and paragangliomas (PPGLs) are rare … treatment very complex. The
aim of this article was to provide practical clinical guidelines for the diagnosis and treatment of …